| Name | Title | Contact Details |
|---|
Icario is a health action company that frees you to help people live healthier lives by helping you connect with them like they`re human. With over 100 million+ member connections, Icario is a health action platform that unites pioneering technology, data science, and behavioral insights to connect everyone to better health. Our mission is to make the world a healthier place, one person at a time. In 2020, Revel + NovuHealth joined forces to create Icario because we knew we could do better together—creating value by uniting pioneering technology, data science, and behavioral insights to make the world a healthier place, one person at a time. There is an island in the Aegean Sea where people live extremely long lives. They`re happy, too. Families are close. They eat well. They exercise. And they stay connected with each other, and not just by smartphone. This got us thinking. What if we apply what we learn from the Blue Zone island of Ikaria (our namesake), add pioneering technology and exabytes of data, and help healthcare connect better with everyone? We`ll have a lot more healthy, happy people, and that`s a pretty good thing. As an organization, we`re a collaborative team of pioneers, inventors, and systems thinkers. We speak truth, are driven by data, and sweat the details. We`re a friendly and easygoing group, but we work hard because we are mission-driven, we know a better way, and we`re here to make it happen.
Greene Health Partners is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Greene Health Partners is based in Xenia, OH. You can find more information on Greene Health Partners at www.greenehealth.org
aaiPharma Inc. (aaiPharma) is a science-based pharmaceutical company offering pharmaceutical development capabilities primarily in the United States and Europe.
Hall Ira is a Sauquoit, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
StemCells, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery primarily in the United States. Its lead therapeutic product candidate, HuCNS-SC cells (purified human neural stem cells), is in development as a potential treatment for a range of central nervous system disorders. The company has conducted a Phase I clinical trial in Pelizaeus-Merzbacher disease, a fatal myelination disorder in children. It is also conducting a Phase I/II clinical trial in chronic spinal cord injury; and has initiated a Phase I/II clinical trial in dry age-related macular degeneration, as well as is pursuing preclinical studies in Alzheimer’s disease. In addition, the company markets a rage of proprietary cell culture products, research grade human cells, and antibody reagents under the SC Proven brand. The proprietary cell culture products include iSTEM, GS1-R, GS2-M, RHB-A, RHB-Basal, NDiff227, NDiff N2, and NDiff N27 supplements, as well as HEScGRO and ESGRO Complete; and antibody reagents comprise STEM24, STEM101, STEM121, and STEM123, which can be used for cell detection, isolation, and characterization. Further, StemCells is involved in developing and commercializing applications of its technologies to enable stem cell-based research. The company sells its tools and technologies products to researchers at academic institutions, pharmaceutical and biotechnology companies, and government laboratories. StemCells, Inc. was founded in 1988 and is headquartered in Newark, California.